Mounjaro®
Starting from £179.99/mo
Start journey Learn moreJabbing early on Mounjaro is possible within a narrow window, but the once-weekly schedule exists for a reason. Tirzepatide's half-life is roughly five days, meaning the drug accumulates in your system on a carefully spaced rhythm — shift that rhythm too far and you risk stacking doses or creating gaps that affect tolerability. The NHS medicines page for tirzepatide advises that if you do need to change your injection day, you should leave at least three days between doses before resetting to the new day going forward. Mounjaro is a prescription-only medicine; how you handle timing is a clinical decision, and your prescriber is the right person to guide it for your specific situation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide is not a medicine that is dosed weekly for convenience alone. Its elimination half-life sits around five days, which means a meaningful amount of each dose is still active when the next one arrives. That overlap is deliberate and part of how steady blood levels are maintained. When the Mounjaro Summary of Product Characteristics on the eMC sets the schedule at once weekly, it is working with that half-life, not against it.
A question our prescribers hear most weeks is whether jabbing a day early matters. The honest answer is: one day early, now and again, is unlikely to cause harm for most people. The concern arises when early doses become a habit. If you consistently inject five or six days after the previous dose rather than seven, you are effectively shortening the interval across every cycle, which can push exposure above what the trials tested and may worsen gastrointestinal side effects during the dose-overlap window.
The other direction is equally worth naming. A dose that is late by a day or two is also manageable; the medicine's long half-life means levels do not fall off a cliff overnight. What matters most is re-anchoring to a consistent weekly day after any adjustment, rather than continuing to drift.
NHS guidance is clear that if you need to move your regular injection day (perhaps because you are travelling, your stock arrives on a different day, or your work pattern has changed) you can do so, provided at least three days have passed since the previous dose. That three-day minimum is the floor. Once you have jabbed on the new day, that becomes your anchor going forward, and you return to weekly from there.
This is different from routinely jabbing early. The three-day rule is designed for a one-off reset, not a rolling pattern of injecting on day five or six every week. If you find that your schedule keeps slipping earlier, that is worth raising with your clinical team rather than quietly accommodating it.
Details on what the practical implications of jabbing one day early look like in real terms are worth reading alongside this page. There is also specific guidance on whether two days early is within the safe window and on what three days early actually means relative to the three-day floor the NHS sets.
Most of the side effects associated with tirzepatide are gastrointestinal: nausea, loose stools, indigestion, a sense of fullness that lingers. These are most prominent after a dose increase or in the early weeks at a new strength, and they broadly track how quickly the medicine's concentration rises in the body. Compressing the dosing interval by repeatedly jabbing early raises that concentration faster than the licensed schedule anticipates.
For people who have already found the tolerability at a given strength manageable, a single early jab is unlikely to trigger anything dramatic. For those still adjusting to a dose step, the timing is worth taking more seriously, and if you are researching suppliers you may want to read our notes on janoshik tirzepatide before making any decisions. The overview of how Mounjaro works covers the dose-escalation schedule in more detail, including why the starter doses exist to settle the system before moving up.
If side effects do become a concern at any point, the right place to start is a conversation with your prescriber, not a change to the injection schedule on your own. The MHRA's Yellow Card scheme also allows anyone to report suspected side effects directly, which contributes to ongoing safety monitoring for medicines like tirzepatide.
If you have already jabbed a day or two early, take stock of when your next dose is due and simply return to weekly from that new date. There is no need to skip a dose to compensate. What matters is preventing further compression of the interval going forward.
If your delivery arrives on a different day each time, that can be a source of scheduling drift worth addressing at source. At nume, sorry, at nume, same-day dispatch and tracked DPD delivery mean the pen arrives predictably, which makes keeping a consistent injection day a good deal simpler in practice.
People considering Mounjaro and thinking through the practical side of managing a weekly injection schedule, including cost over time, may find the context on Mounjaro pricing in the UK a useful companion read. And for anyone who wants their specific circumstances reviewed by a clinician, the starting point is always a consultation. Check your eligibility with our prescribers and get a clear picture of whether Mounjaro is right for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.